Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia

Completed · Phase 1

Conditions studied: Leukemia

In brief

RATIONALE: Immunotoxins, such as anti-CD19 and anti-CD22, can find cancer cells that express CD19 and CD22 and kill them without harming normal cells. This may be an effective treatment for B-cell acute lymphoblastic leukemia. PURPOSE: This phase I trial is studying the side effects and best dose of anti-CD19 and anti-CD22 immunotoxins in treating patients with refractory or relapsed B-cell acute lymphoblastic leukemia.

Key facts

Study ID

NCT00450944

Run by

Albert Einstein College of Medicine

People needed

10

Starts

2006-02-22

Expected to finish

2010-04-01

Last updated by the study team

2021-04-14

Who can join

Age: 17 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Albert Einstein Cancer Center at Albert Einstein College of Medicine — The Bronx, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.